Bharat Biotech s Covaxin found to neutralise 617 variant of COVID-19: US advisor Dr Fauci
Fauci, who is US President Joe Biden s chief adviser on the Covid pandemic, quoted the recent Phase 3 clinical trials of Covaxin by ICMR. (Image: Reuters)
Updated: Apr 28, 2021, 09:50 PM IST
The made-in India Covaxin vaccine, developed by Hyderabad-based Bharat Biotech, can neutralise the B1617 variant of coronavirus, said White House s chief medical adviser Dr Anthony Fauci. Now, this is something we are still gaining data on, but most recent data looking at convalescent sera of Covid-19 cases in people who received Covaxin, it was found to neutralise the 617 variant, Fauci was quoted as saying during the White House press briefing.
Want to take Covid vaccine? Here’s how you can register on CoWIN, Aarogya Setu
Here are the steps on how one can register for the vaccine using the CoWIN Portal and Arogya Setu app.
By Sakina Fatima| Updated: 28th April 2021 11:15 pm IST Registration for phase-3 of Largest Vaccine Drive began today at 4:00 PM.
The third phase of the COVID-19 vaccination drive for the people who have attained 18-years of age and above is set to kick off from May 1.
Currently there are two COVID vaccines being administered in India. These includes the Covaxin that has been developed by Hyderabad-based Bharat Biotech, and Covishield that has been developed by the Oxford-AstraZeneca and is being manufactured by the Serum Institute of India.
This is a continuation of the phase-2 trials to see if the booster dose triggers the long-term memory cells or plasma cells enough to memorise the immunity and give lifelong immunity to the system.
CHENNAI: Seven people got a third booster dose of Covaxin on Monday at SRM Medical College Hospital and Research Centre (SRM MCHRC), six months after they received the second dose, as part of a study to find out if it gives immunity for a longer period.
A total of 190 people will receive the booster dose in eight different sites including New Delhi, Patna and Hyderabad. Some 20 to 25 people will receive the shot at SRM.
Central government asks Serum Institute and Bharat Biotech to lower price of COVID-19 vaccines, say official sources
Central government asks Serum Institute and Bharat Biotech to lower price of COVID-19 vaccines, say official sources
PTIApr 27, 2021, 09:02 IST
TOI
Bharat Biotech to lower prices of their
COVID-19 vaccines amid criticism from various states who objected to profiteering during such a major crisis. The issue of Now the two companies are expected to come up with revised pricing for their vaccines.
Advertisement
price of its COVID-19 vaccine, Covaxin, at ₹600 per
dose for The Pune-based
Serum Institute of India (SII), the world s largest vaccine maker in terms of volume, has announced a price of ₹400 per dose for its COVID-19 vaccine, Covishield , for state governments and ₹ 600 per dose for private hospitals.
Bill Gates Rejects COVID-19 Vaccine Patent Waivers as Shot-Maker India Buckles Under Second Wave
Subscribe
Sputnik International
https://sputniknews.com/asia/202104271082735438-bill-gates-rejects-covid-19-vaccine-patent-waivers-as-shot-maker-india-buckles-under-second-wave/
Pune’s Serum Institute, the world’s largest vaccine factory, has helped fill massive orders for AstraZeneca’s COVID-19 vaccine CoviShield in Europe and the US. But while rich nations with just 16% of the world’s population have gotten roughly 47% of the 1 billion COVID-19 vaccine shots administered, poor nations have gotten just 0.2% of the shots.
The founder of Microsoft and one of the world’s wealthiest men, Bill Gates, has dismissed the growing movement to waive intellectual property rights to COVID-19 vaccines, which would allow poorer nations to get their lists of ingredients and produce their own versions. Instead, they will have to wait in line until wealthier nations protect themselves and p